Ensign Peak Advisors
BCAX

Ensign Peak Advisors’s Bicara Therapeutics BCAX Stock Holding History

Ensign Peak Advisors’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.98M Hold
401,444
– – 0.01% 452
2025
Q4 		$6.76M Buy
+401,444
New +$6.86M 0.01% 478

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Ensign Peak Advisors's BCAX Position: Q1 2026 in Review

Ensign Peak Advisors held its Bicara Therapeutics (BCAX) position steady in Q1 2026 at 401,444 shares worth $7.98M. The position accounts for 0.01% of the portfolio, ranked #452.

Ensign Peak Advisors first reported a position in BCAX in Q4 2025 and has held it in 2 quarters since. 146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

  • Ensign Peak Advisors held 401,444 shares of Bicara Therapeutics worth $7.98M as of Q1 2026.
  • Ensign Peak Advisors left its Bicara Therapeutics share count unchanged in Q1 2026.
  • Bicara Therapeutics made up 0.01% of Ensign Peak Advisors's portfolio in Q1 2026, its #452 holding.
  • Ensign Peak Advisors first reported a position in Bicara Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Ensign Peak Advisors's 13F filing for Q1 2026, filed 13 May 2026.